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Abstract
Objective The aim of this study was to investigate the
impact of pregabalin on pain, other symptoms, and patient-
reported outcomes for patients with uncontrolled pain who
have been referred to pain clinics.
Patients and Methods Adult patients with uncontrolled
pain who had a score of C4 in the DN4 questionnaire were
evaluated at baseline, month 3, and month 6. Evaluations
included pain levels using a visual analog (VAS) scale as
well as anxiety, depression, sleep, disability, and treatment
satisfaction employing validated tools.
Results Our sample comprised 413 patients who met the
selection criteria, had not received pregabalin previously,
and were prescribed pregabalin at the study initiation,
mainly (97 %) as add-on therapy. Overall, patients had a
statistically significant reduction in VAS pain score of 41
points (54 % reduction, p \ 0.001), varying from 64 %
reduction (oncological pain) to 31 % reduction (central
neuropathic pain). Effect sizes for anxiety, depression,
sleep, and treatment satisfaction improvement were mod-
erate to large depending on the dimension and clinical entity.
Conclusion Our results suggest that in patients with
uncontrolled neuropathic pain of various origins who were
treated at pain clinics, the addition of pregabalin to a wider
pharmacological treatment regimen was associated with a
clinically relevant improvement of pain and psychological
well-being and a reduction in the impact of neuropathic
pain on daily activities. Add-on treatment with pregabalin
was well tolerated.
Key Points
Refractory or uncontrolled neuropathic pain is
common and is associated with significant burden.
Our results suggest that in patients with uncontrolled
neuropathic pain of various origins who were treated
at pain clinics, treatment with pregabalin as part of a
wider pharmacological regimen is associated with a
significant improvement of pain, an improvement of
anxiety and depressive symptoms, a reduction in
sleep disturbance, and an amelioration of the
interference of the disease with the patient’s life.
1 Introduction
The management of neuropathic pain requires an interdis-
ciplinary approach in which pharmacological treatment is
cardinal [1]. Although the epidemiologic information on
refractory neuropathic pain is limited [2], there is a general
agreement that many patients with neuropathic pain are
refractory or unable to tolerate existing treatments [3, 4]. In
fact, several surveys carried out in Europe and the US have
shown that although patients with neuropathic pain receive
several drugs for pain treatment, moderate to severe levels
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of pain are common and are associated with a significant
burden in terms of reduced quality of life, loss of produc-
tivity, and increased use of health resources [5–8].
Pregabalin is an a2-d ligand that, in randomized con-
trolled trials, has been demonstrated to be effective for the
treatment of several peripheral or central neuropathic
painful conditions such as diabetic neuropathy, postherp-
etic neuralgia, trigeminal neuralgia, and the central neu-
ropathic pain associated with spinal cord injury, among
others [9]. Several non-randomized studies have evaluated
the impact of pregabalin for the treatment of refractory
neuropathic pain [10–18]; however, these studies were
carried out in a primary care setting [10, 11, 13, 14], were
focused on specific clinical entities [10, 12, 17], specifi-
cally evaluated patients refractory to gabapentin [13, 14],
and/or used an economic model for the evaluation [15, 16].
In addition, patients with neuropathic pain, especially those
with refractory pain, are commonly treated by combining
two or more drugs [19]. Although there are some ran-
domized trials on the use of pregabalin combined with
other pharmacological treatment in patients with neuro-
pathic pain [20–23], none addressed the treatment of
refractory pain. It has been suggested that the treatment of
neuropathic pain should be aimed at the mechanism
underlying the specific type of pain [24]. The effect of
pregabalin on the different types of neuropathic pain (i.e.
the different types of spontaneous or evoked pain) has
scarcely been investigated.
The aim of this report was to investigate the impact of
pregabalin on pain, other symptoms, and patient-reported
outcomes for patients with uncontrolled pain who were
referred to pain clinics. We also aimed to explore the
results of pregabalin treatment in this population according
to the underlying clinical entity and type of pain.
2 Patients and Methods
The UNIDOL study was an observational, multicenter,
prospective study performed by 161 investigators from
pain clinics throughout Spain between February 2009 and
February 2010 with the aim of evaluating the clinical
profile and previous management of patients with uncon-
trolled neuropathic pain who were referred to pain clinics.
The study was approved by the Ethics Committee of the
Hospital General Universitario de Valencia (Spain). Writ-
ten informed consent was obtained from every subject. The
study was carried out in accordance with the principles
contained in the Declaration of Helsinki.
To be included in the UNIDOL study, patients had to be
18 years of age or older, have been referred to a pain clinic
with uncontrolled pain, and have a score equal to or greater
than 4 in the DN4 questionnaire. Patients were excluded if
they were unable to understand the study objectives or
fulfill the study self-administered questionnaires. Results
for the whole cohort (i.e. 728 evaluable patients) presenting
data on the clinical profile and previous management of
patients with uncontrolled neuropathic pain who were
referred to pain clinics have been accepted for publication
elsewhere [25]. We present herein the results of an analysis
of the subset of patients from the UNIDOL cohort who had
not received pregabalin previously and were prescribed this
drug upon entry to the study (n = 413).
2.1 Study Assessments
At baseline, the following information was recorded: so-
ciodemographic data, type of specialist referring the
patient, diagnostic confirmation of neuropathic pain, con-
firmation of the presence of uncontrolled pain as judged by
the investigator, etiology and duration of pain, causes for
uncontrolled pain, and pain intensity as measured with a
0–100 mm visual analog scale (VAS). Investigators were
asked to record the presence and severity of the several
types of evoked or spontaneous neuropathic pain based on
the physical examination and/or clinical interview. We also
recorded pharmacological and non-pharmacological treat-
ment for neuropathic pain. In addition, the Spanish vali-
dated versions of the following questionnaires and scales
were fulfilled: DN4 questionnaire, Hospital Anxiety and
Depression Scale (HADS), Medical Outcomes Study Sleep
Scale (MOS-Sleep), the World Health Organization Dis-
ability Assessment Schedule (WHO-DAS II), and the
Treatment Satisfaction with Medicines Questionnaire
(SATMED-Q). Clinical evaluations were also administered
at months 3 and 6.
The neuropathic pain diagnostic questionnaire DN4
consists of 10 items describing different pain characteris-
tics. A score of at least 4 of 10 possible points is considered
to identify neuropathic pain with 83 % sensitivity and
90 % specificity [26–28].
The HADS is a self-administered instrument consisting
of 14 items: seven items exploring depression symptoms,
and the other seven exploring anxiety symptoms [29, 30].
Each item score ranges from 0 to 3, where 0 represents the
absence of that symptom and 3 represents the highest
severity or frequency of the symptom. By adding the seven
items of each subscale, two scores ranging from 0 to 21 are
obtained for depression and anxiety (HADS-D and HADS-
A, respectively).
The MOS-Sleep is also a self-administered question-
naire evaluating key aspects of sleep [31, 32]. It consists of
12 items composing six subscales or domains: sleep dis-
turbances, snoring, shortness of breath or headache upon
awakening, adequacy of sleep, day somnolence, and
amount of sleep. In addition, the MOS-Sleep provides a
834 J.-L. de la Calle et al.
summary index of sleep disturbances that can be obtained
from nine of its item scores; the higher the score, the worse
the sleep, with the exception of amount of sleep and ade-
quacy of sleep dimensions, which are scored in the oppo-
site direction. In patients with neuropathic pain, this scale
has shown adequate psychometric properties [32].
The WHO-DAS II comprises 12 items that evaluate an
individual’s level of functioning and disability in six areas:
understanding and communicating, getting around, self-
care, getting along with people, life activities, and partic-
ipation in society [33–35]. Patients are required to answer
questions regarding how many difficulties they had in the
last 30 days due to their health condition, on a 5-point scale
from 1 (none) to 5 (extreme difficulty or cannot do it). Raw
scores are transformed into a standard scale ranging from 0
to 100, with higher scores reflecting greater disability. A
global score is obtained that ranges from 0 to 700 (if work
activities outside the home are assessed) or from 0 to 600.
The SATMED-Q is a self-administered questionnaire
involving 17 items that evaluate six dimensions: treatment
effectiveness, convenience of use, impact on daily activi-
ties, medical care, global satisfaction, and undesirable side
effects [36, 37]. Regarding the side effects, the SATMED-
Q records information about whether the patient has
experienced side effects with the medication, and contains
three questions addressing how the side effects interfere
with physical activity, leisure and free-time activities, and
daily activities. It also provides a global score for satis-
faction with drug treatment by summing up the scores of all
domains. Raw scores are transformed into a scale ranging
from 0 to 100, with greater scores indicating higher
satisfaction.
2.2 Statistical Analysis
Quantitative variables were described using means and
standard deviations (SDs) and qualitative variables with
absolute and relative frequencies. The changes from
baseline to month 6 in the previously-mentioned scales and
subscales scores, including the pain intensity VAS, were
used as outcome variables. In addition, the percentage of
patients with a reduction of at least 50 % in pain intensity,
as rated by VAS pain, was calculated, and these patients
were defined as responders.
The significances of within-group changes from baseline
to endpoint in the total scores or subscores of the scales and
questionnaires were calculated using Student’s t-test or a
non-parametric test; for binary outcomes, we used the
McNemar test. Effect sizes for these within-group changes
were also calculated using the difference of means, before
and after treatment, of a particular measure, divided by the
SD of that measure before treatment [38]. For effect size
interpretation, the established criterion of considering 0.20
to \0.50 to be a small effect size, C0.50 to \0.80 to be
moderate, and C0.80 to be large was used [38].
3 Results
3.1 Patient Disposition and Demographic and Clinical
Characteristics
Originally, 755 patients were included in the UNIDOL
cohort. We excluded 27 (3.6 %) patients who did not meet
the selection criteria, leaving 728 evaluable patients in the
cohort. From those patients, 413 patients had not received
pregabalin previously, were prescribed pregabalin at the
study initiation, and constituted the sample for these
analyses and subsequent report. Overall, 34 of the 413
patients (8.2 %) discontinued their participation in the
study.
Patients’ demographic and clinical characteristics are
described in Table 1. Patients had a mean age of 58 years
and were predominantly women (62 %). Patients had
severe pain with a mean VAS score of 76, a mean duration
of pain over 2 years, and a mean DN4 score of 6.6. The
most common cause of neuropathic pain was radiculopathy
(44 %), followed by pain of oncological origin [i.e.
malignant-, radiation-, or chemotherapy-induced pain]
(14 %) and neuralgia (9 %). With the exception of thermal
allodynia, reported in 64 % of the patients, each type of
spontaneous or evoked pain was reported by at least 75 %
of the patients.
There were no differences in pain severity or duration of
pain among the several clinical entities included in this
analysis (data not shown). However, the mean DN4 score
differed significantly among these clinical entities
(p \ 0.001), with patients with central neuropathic pain
(7.7), diabetic neuropathy (7.6), complex regional syn-
drome (7.5), and other neuropathies (7.0) showing the
highest scores on this scale. The remaining clinical entities
have the following DN4 scores: oncological pain (6.9),
trigeminal neuralgia (6.6), post-surgery/trauma (6.4), other
neuralgia (6.4), radiculopathy (6.3), nerve entrapment
syndrome (6.2), and plexopathy (5.7).
3.2 Treatment Characteristics
Treatment characteristics are described in Table 2. The
vast majority of patients (97 %) received pregabalin as
add-on therapy. The mean (±SD) final dose of pregabalin
was 319 ± 375 mg/day in patients receiving pregabalin
add-on and 209 ± 114 mg/day in those receiving pregab-
alin monotherapy. In patients receiving pregabalin add-on,
the dose varied greatly depending on the clinical entity;
patients with plexopathy (585 ± 664 mg/day) and those
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with trigeminal neuralgia (576 ± 452 mg/day) received
the higher doses, whereas patients with radiculopathy
received the lower doses (242 ± 244 mg/day). Almost
three-quarters of patients received at least four drugs for
the treatment of neuropathic pain, with the most common
being opioids (61 %), antidepressants (50 %) and, to a
much lesser extent, non-steroidal anti-inflammatories
(23 %). The doses of the most commonly prescribed drugs
are presented in Table 3. Two-thirds of the patients were
also receiving non-pharmacological interventions.
3.3 Treatment Outcomes for the Overall Sample
and by Clinical Entity
Overall, patients treated with add-on pregabalin showed a
statistically significant reduction of VAS pain score of 41
points (54 % reduction), from a baseline mean score of 76
points to an endpoint mean score of 35 (Table 4). Patients
with oncological pain (64 % reduction), complex regional
pain syndrome (61 % reduction), and trigeminal neuralgia
(59 % reduction) had the largest reductions in VAS pain
score, whereas patients with central neuropathic pain
showed the lowest reduction (31 % reduction). The effect
sizes for these changes were large for all clinical entities,
with the exception of central neuropathic pain, which was
moderate. At study completion, 79 % of patients showed a
reduction of pain intensity of at least 50 % from baseline
(i.e. responders). The proportion of responders was higher
among those with oncological pain (88 %) and complex
regional pain syndrome (87 %), and lower among patients
with central neuropathic pain (50 %) and patients with
diabetic neuropathy (58 %).
There were no differences in the improvement of pain
according to the type of pain (spontaneous or evoked)
[Table 5]. In fact, the proportion of responders (VAS pain
reduction C30 %) varies from 87 % in patients with par-
esthesias to 89.4 % in patients with mechanical
hyperalgesia.
Significant and clinically relevant improvements (i.e.
effect sizes moderate) were observed in all other dimen-
sions of the disease (Table 4). The percentage reduction
over the 6 months of pregabalin treatment was 39 % for
anxiety, 35 % for depression, and 38 % for sleep disorders.
The proportion of patients with bad or very bad health
according to the WHO-DAS II was reduced from 51.4 % at
baseline to 9.2 % at month 6. Similarly, the proportion of
patients with severe or extreme interference with life was
reduced from 44 % to 14 % during the same period.
Treatment satisfaction, as evaluated with the SATMED-Q
total score, increased 50 % compared with the baseline
score. Regarding improvement of these dimensions of the
disease by clinical entity, the results followed a similar
pattern to that previously mentioned for pain: patients with
complex regional syndrome, plexopathy, and trigeminal
neuralgia exhibited better results, whereas lesser
improvements were reported in patients with central neu-
ropathic pain and in patients with diabetic neuropathy and
other neuropathy. Effect sizes for anxiety, depression,
sleep, and treatment satisfaction improvement were mod-
erate to large depending on the dimension and clinical
entity (Table 4). Despite effect sizes for most dimensions
in patients with central neuropathic pain being only mod-
erate, the effect size for the treatment satisfaction was
large.
3.4 Tolerability
The proportion of patients experiencing side effects
according to the question included in the SATMED-Q
significantly increased from 51 % at baseline to 65 % at
Table 1 Demographic and clinical characteristics
Characteristic N Value
Age [years; mean ± SD] 393 57.93 ± 13.83
Sex [female; n (%)] 402 249 (61.9)
BMI [kg/m2] 357
Mean ± SD 26.72 ± 4.41
DN4 (0–10) [mean ± SD] 413 6.55 ± 1.54
VAS [mean ± SD] 398 75.55 ± 14.94
Duration of pain [years; mean ± SD] 408 2.26 ± 3.40




Nerve entrapment syndrome 27 (6.9)
Plexopathy 16 (4.1)





Central neuropathic pain 10 (2.6)
Other neuropathic pain 9 (2.3)





Evoked pain [n (%)] 385
Static allodynia 300 (77.9)
Dynamic allodynia 308 (79.6)
Thermal allodynia 239 (63.9)
Mechanical hyperalgesia 322 (82.1)
Hyperpathia 281 (74.1)
BMI body mass index, SD standard deviation, VAS visual analog scale
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month 3 (p \ 0.001 for the comparison with baseline) and
58 % at month 6 (p \ 0.05). The overall interference of
side effects with patient’s activities, as measured with the
corresponding dimension of the SATMED-Q, increased
slightly but significantly from a score of 75.5 at baseline to
a score of 81.3 at endpoint (i.e. a 7.7 % increase).
4 Discussion
Our results suggest that, in patients with uncontrolled
neuropathic pain of various origins who were treated at
pain clinics, treatment with pregabalin as part of a wider
pharmacological regimen is associated with a relevant and
significant improvement of pain, an improvement of anx-
iety and depressive symptoms, a reduction in sleep dis-
turbance, and an amelioration of the interference of the
disease with the patient’s life.
Pregabalin in combination with other drugs produced a
substantial improvement in pain, i.e. a 54 % reduction in
pain severity. In fact, almost 80 % of the patients were
considered responders (i.e. had a reduction of at least 50 %
in the VAS pain score). Previous studies with pregabalin in
patients categorized as refractory have shown good but
more modest results. In an analysis of 81 patients who had
moderate to severe neuropathic pain despite treatment with
gabapentin, a tricyclic antidepressant, and a third drug,
Stacey and coworkers reported a mean improvement of
34 % in the VAS score of the Short-Form McGill Pain
Questionnaire, and a proportion of responders of 39 % and
35 % after 3 and 15 months, respectively, of pregabalin
treatment [39]. However, these authors use a selected
sample of patients who had previously participated in
double-blind, placebo-controlled trials of pregabalin in
patients with diabetic peripheral neuropathy or postherpetic
neuralgia. The results from observational studies of short-
term treatment with pregabalin show a proportion of
responders of 43 % in 174 patients with neuropathic pain
who were refractory to gabapentin and were treated in
primary care environments (34 % in patients who received
pregabalin add-on) [14], 54 % in 244 patients with
refractory neck pain treated in orthopedic surgery and
rehabilitation clinics [12], and 62 % in 564 patients with
refractory low-back pain treated in orthopedic surgery and
rehabilitation clinics [17]. Although the differences in the
design, outcome measures and, in particular, underlying
disease may account for the differences between our results
and the results of these studies, we believe that they cannot
entirely explain such a large difference. The lack of a
control group could have overestimated the treatment
effects in our study; however, the same criticism could be
applied to all previous studies. In our view, a plausible
explanation is the setting in which the patients were trea-
ted. Patients in the present study were treated at pain
clinics, and therefore it is likely that, in this setting, treat-
ment was optimized to a greater extent than in patients
treated by a primary care physician or other specialists.
Interestingly, the mean dose of pregabalin in the present
study (319 mg/day) was higher than in the above-men-
tioned studies, 222 mg/day in the study involving primary
care [14], and 190 mg/day in the study of patients with
refractory low-back pain attended to by specialists [17].
This finding supports our hypothesis of greater treatment
optimization at the pain clinics compared with other
Table 3 Doses of the most
commonly (N C10) prescribed
drugs with pregabalin
AED antiepileptic drugs,
N number of patients who
received the drug, n number of
patients with available




Drug N n Dose [mean ± SD]
Paracetamol (mg/day) 90 86 2,576.8 ± 921.9
NSAIDs (mg/day)
Ibuprofen 39 38 1,194.74 ± 456.16
Metamizole 35 32 2,204.13 ± 1,207.85
Diclofenac 12 12 106.25 ± 37.12
Dexketeprofen 10 10 65.63 ± 18.60
Opioids
Tramadol (mg/day) 172 169 207.54 ± 113.59
Fentanyl (lg/h) 65 62 18.60 ± 15.61
Oxycodone (mg/day) 96 93 34.19 ± 29.57
Hydromorphone hydrochloride (mg/day) 17 17 8.24 ± 8.54
AED [other than pregabalin] (mg/day)
Gabapentin 38 38 1,334.7 ± 660.4
Carbamazepine/oxcarbazepine 12 12 650 ± 416.7
Antidepressants (mg/day)
Duloxetine 88 87 49.2 ± 17.7
Amitriptyline 121 121 32.19 ± 18.56
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settings as the reason for the better results in the present
study than in previous studies.
The results from other secondary efficacy outcomes
are consistent with, and support, those obtained on pain.
Relevant improvements in anxiety, depression, sub-
jective sleep quality, and quality of life were observed
after treatment with add-on pregabalin. This improve-
ment in other dimensions of neuropathic pain is consis-
tent with what it is known from randomized clinical trials
in patients with neuropathic pain [9] and from previous
studies on patients with refractory neuropathic pain [12,
14, 17, 40].
Although the results should be interpreted cautiously
due to the nature of the analyses, the lack of a control
group, and the small sample size for some subgroups, our
analyses revealed that add-on pregabalin was similarly
effective across all clinical entities studied. Patients with
diabetic neuropathy, particularly those with central neu-
ropathic pain, exhibited more modest results, with reduc-
tions in pain severity of 44 % and 31 %, respectively, and
response rates of 58 % and 50 %, respectively. As we will
comment below, these subgroups of patients had a higher
score on the DN4 questionnaire. Whether this higher score
reflects a worse clinical condition or a greater neuropathic
component of the pain is impossible to answer. Pregabalin
has consistently been demonstrated, in several randomized
clinical trials, to be effective for the treatment of painful
diabetic neuropathy, and in fact is considered a first-line
option for the treatment of this condition in most clinical
guidelines [9]. Central neuropathic pain is very disabling
and difficult to treat, and only a few drugs in a few studies
have shown positive results for this condition [9]. Pre-
gabalin has been shown to be significantly more effective
than placebo in three of the four studies carried out in
patients with central neuropathic pain [9], including a
recent trial in patients with neuropathic pain secondary to
spinal cord injury [41]. However, whereas the response
rates in these studies were 22 % and 35%, the response
rates in randomized trials of pregabalin in painful diabetic
neuropathy were usually over 45 % [9]. Our results in
patients with central neuropathic pain are consistent with
this latter observation, indicating that although pregabalin
is useful for the treatment of these patients, we must expect
more modest benefits when treating patients with central
neuropathic pain than in other conditions. The effect of
pregabalin was almost identical across the several types of
spontaneous or evoked pain; however, this subgroup ana-
lysis was difficult to interpret because most patients pre-
sented most types of pain.
The tolerability of pregabalin, as evaluated with the
SATMED-Q, was good. Although there was an increased
impact from side effects on the patients’ lives, the effect
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benefits of the drug because treatment satisfaction
increased by 50 % at the endpoint.
In addition to the limitations mentioned, another poten-
tial limitation of our study was whether the patients inclu-
ded had truly refractory neuropathic pain. This issue is
difficult to solve because despite recent initiatives [42],
there is no standard definition for refractoriness. A recent
survey has shown that non-optimized treatment is more
frequent than truly treatment-refractory neuropathic pain in
the community setting [43]. However, regardless of whether
they are labeled as having refractory or uncontrolled pain,
several factors appear to indicate that the patients included
in this study were suffering disabling and very difficult-to-
treat neuropathic pain. Almost half of the patients reported
having bad or very bad health and that the interference of
their health condition with their lives was severe or extreme.
More importantly, for pain management, the patients
required a complex pharmacological regimen that included
an opioid in almost two-thirds of the patients. Finally, it is
important to stress that patients received pregabalin as part
of a more complex pharmacological regimen; therefore, the
attributable benefit to pregabalin in this population of
patients with uncontrolled pain can only be elucidated in a
randomized controlled trial.
It interesting to note that after initiating add-on pre-
gabalin, the clinical entities with poorer results on pain
amelioration and other secondary efficacy outcomes were
central neuropathic pain and diabetic neuropathy, and these
entities were those presenting the higher baseline score in
the DN4 questionnaire. It is therefore possible that the use
of the DN4 questionnaire could help to screen the presence
of refractory neuropathic pain, a possibility that is worth
evaluating in further psychometric studies of this assess-
ment tool.
5 Conclusions
Despite the limitations of this study, these results suggest
that, in the clinical practice setting, the addition of pre-
gabalin to the previous treatment might be a useful alter-
native for the treatment of uncontrolled neuropathic pain. It
would be worthwhile to carry out randomized clinical trials
of pregabalin in patients with refractory pain that could
confirm our positive results. The use of active comparators
could help to delineate the role of pregabalin for treating
refractory neuropathic pain.
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